Rigel Pharmaceuticals RIGL Gross product sales — Revenue recognized
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's gross product sales — revenue recognized.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's gross product sales — revenue recognized?
- Rigel Pharmaceuticals (RIGL) reported gross product sales — revenue recognized of $75.39M in Q1 2026.
- How has Rigel Pharmaceuticals's gross product sales — revenue recognized changed year-over-year?
- Rigel Pharmaceuticals's gross product sales — revenue recognized increased by 25.2% year-over-year, from $60.19M to $75.39M.
- What is the long-term trend for Rigel Pharmaceuticals's gross product sales — revenue recognized?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's gross product sales — revenue recognized has grown at a 39.8% compound annual growth rate (CAGR), from $81.19M to $309.96M.
- What does gross product sales — revenue recognized mean?
- This metric represents the total revenue recognized from the sale of pharmaceutical products to customers, excluding any assessed taxes. It serves as a primary indicator of the commercial adoption and market demand for the company's proprietary drug portfolio. By isolating product-related income, it allows investors to assess the core operational performance and revenue generation capabilities of the firm's therapeutic offerings.